AVEO Pharmaceuticals
Patents, Design & Utilities

Last updated:

List of all AVEO Pharmaceuticals patents 12 in total

Status Patent
Application
Utility: USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER External link
Filling date: 6 Sep 2025 Issue date: 28 Jul 2022
Application
Utility: ANTI-NOTCH3 ANTIBODY External link
Filling date: 6 Sep 2025 Issue date: 28 Jul 2022
Application
Utility: USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER External link
Filling date: 6 Sep 2025 Issue date: 6 Jan 2022
Application
Utility: ANTI-NOTCH3 ANTIBODIES External link
Filling date: 6 Sep 2025 Issue date: 10 Jun 2021
Application
Utility: ANTI-GDF-15 ANTIBODIES External link
Filling date: 6 Sep 2025 Issue date: 8 Apr 2021
Application
Utility: ANTI-ERBB3 ANTIBODIES External link
Filling date: 6 Sep 2025 Issue date: 24 Sep 2020
Grant
Utility: Anti-NOTCH3 antibodies External link
Filling date: 6 Sep 2025 Issue date: 18 Aug 2020
Grant
Utility: Anti-GDF15 antibodies External link
Filling date: 6 Sep 2025 Issue date: 24 Mar 2020
Grant
Utility: Anti-ERBB3 antibodies External link
Filling date: 6 Sep 2025 Issue date: 3 Dec 2019
Application
Utility: METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT External link
Filling date: 6 Sep 2025 Issue date: 26 Sep 2019
Application
Utility: TREATMENT OF CHRONIC KIDNEY DISEASE AND OTHER RENAL DYSFUNCTION USING A GDF15 MODULATOR External link
Filling date: 6 Sep 2025 Issue date: 26 Sep 2019
Application
Utility: TREATMENT OF CONGESTIVE HEART FAILURE AND OTHER CARDIAC DYSFUNCTION USING A GDF15 MODULATOR External link
Filling date: 6 Sep 2025 Issue date: 26 Sep 2019

Showing 1 to 12 of 12 patents.